Clinical Validation Report on IVD Reagents

Product name: SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography)

Model and specification: 25 tests/kit, each test strip packaged separately

Type of clinical trial: Clinical validation

Completion date: August 21, 2020

Testing agency: IPE Center for Clinical Laboratory

Abstract

To evaluate the SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography) (the "Test Kit" for short) produced by Beijing Lepu Medical Technology Co., Ltd. ("the Company" for short) for clinical application in qualitative detection of the content of SARS-CoV-2 antigen in clinical samples (nasal swab samples), IPE Center for Clinical Laboratory conducted a clinical study on the test strip therein. A total of 210 nasal swab samples were selected as the study objects, including 75 positive samples and 135 negative samples confirmed by COVID-19 diagnosis and treatment protocol. The kits used for diagnosis was 2019-nCoV PCR Kit (fluorescent PCR method) (GXZZ 20203400179) produced by Beijing Applied Biological Technologies Co., Ltd. was used as the reference kit. Based on the test result of the reference kit, the study objects were divided into 2019-nCoV antigen positive group and 2019-nCoV antigen negative group. At the same time, these samples were tested with the Test Kit, and the test results of the Test Kit and the reference kit were compared and statistically analyzed. The results showed that the negative coincidence rate, positive coincidence rate and total coincidence rate between the Test Kit and the reference kit all were greater than 90%, indicating that the Test Kit is in good consistency with the reference kit, and suitable for clinical auxiliary diagnosis.

I. Introduction

As a large virus family, 2019-nCoV is a single strand plus RNA virus with an envelope. It can cause major diseases such as colds, Middle East Respiratory Syndrome (MERS), and severe acute respiratory syndrome (SARS). SARS-CoV-2 was officially named by the World Health Organization on January 12, 2020. The core protein of SARS-CoV-2 is N protein (Nucleocapsid) inside. It is relatively conserved among β -coronaviruses and is often used for the diagnosis of coronaviruses. As the key recipient for SARS-CoV-2 to enter the cells, ACE2 is of great significance to study the viral infection mechanism.

The research and development work of the Test Kit produced by the Company has been completed. Clinical validation work has been started in order to validate the suitability and accuracy of the test strip in clinical application. Entrusted by the Company, IPE Center for Clinical Laboratory undertook the clinical trial on 210 test samples with the Test Kit produced hereby in the clinical study.

II. Purpose

The clinical performance of the Test Kit produced by the Company will be systematically studied in order to validate its suitability and accuracy in clinical application.

The purpose of this clinical trial is to conduct the comparative experimental study for the same clinical sample with the Test Kit "SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography)" produced by the Company and the reference kit "2019-nCoV PCR Kit (fluorescent PCR method)" (GXZZ 20203400179) produced by Beijing Applied Biological Technologies Co., Ltd.. Statistical analysis was carried out on the test results to calculate the negative coincidence rate, positive coincidence rate and total coincidence rate. According to the results of statistical analysis, it was validated that the Test Kit is equivalent to the reference kit, so as to validate the suitability and accuracy of the Test Kit for clinical auxiliary diagnosis.

The results of this clinical trial are an important basis for evaluating the efficacy and safety of the Test Kit.

III. Test Management

1. Introduction to management structure

The clinical trial was conducted by the clinical trialing agency IPE Center for Clinical Laboratory. As the applicant, the Company was responsible for communication and contact during the clinical trial.

2. Quality control in the laboratory

1) All researchers participating in this clinical trial passed the qualification examination and had professional background and capacity related to clinical trial. Before the clinical trial, all researchers had a full understanding of the specific contents about the clinical trial protocol and all indexes through training.

- 2) The quality control of the laboratory met the requirements of quality control of clinical laboratory to ensure the standardization of test procedure.
- 3) Quality control before the analysis: Sample collection and treatment was checked for compliance with the requirements and, sample number and other information were checked for correctness.
- 4) The execution and completion of clinical trial was inspected regularly. The completeness and precision of clinical sample information was checked and the test results were verified.
- 3. Statistics and data management
- 1) All selected cases were filled in the clinical outcome summary sheet, including the subjects' sample number, age, gender, and so on. The testers filled the test results of the reference kit and the Test Kit in the clinical outcome summary sheet.
- 2) After finishing data entry, the main researchers, testers and applicant jointly reviewed the data and locked the data when they had no doubt.
- 3) The clinical outcome summary sheet was then sent to analysts for statistics and analysis. The obtained statics and analysis results were incorporated into corresponding parts of the clinical report.

4. Data preservation

The testing agency and the applicant kept one copy of clinical trial data respectively, including the following contents:

Clinical Trial Agreement, Clinical Test Protocol, Ethics Committee Instructions, Clinical Test Report (testing agency's report), General Report on Clinical Trial, and Clinical Outcome Summary Sheet.

5. Problems found in the study and treatment measures

In clinical trials, when a small number of samples are tested, the results of control samples and test samples are inconsistent. In this case, the clinical quantitative data of these samples or other common clinical strips produced with the same principle are used for re-test.

IV. Test Design

Description of overall test design and protocol

With reference to the *Guideline of Clinical Study on In Vitro Diagnostic Reagents*, the appropriate study objects are selected and the 2019-nCoV PCR Kit (fluorescent PCR method) (GXZZ 20203400179) that was approved for marketing was used as the reference kit to conduct blinding simultaneous comparison, for analyzing the negative coincidence rate, positive coincidence rate and total coincidence rate of the Test Kit and the reference kit.

The trial protocol was to select 210 nasal swab samples as the study objects. Samples were divided into positive group and negative group according to the test results of reference kit. At the same time, the samples were tested with qualitative test strip and reference agent, the test results of the Test Kit and the reference agent were compared and statistically analyzed to

calculate the negative coincidence rate, positive coincidence rate and total coincidence rate, so as to judge the clinical suitability and accuracy of the Test Kit, and whether the test result of the Test Kit was consistent with that of the reference kit.

Research method

Sample collection, storage, transportation

After the samples were collected, they were placed in the sample treatment solution, stored at $2-8\,^{\circ}$ C and tested within 24 h. The samples should not be stored for a long time at room temperature.

Determination of method for comparison

Since the 2019-nCoV PCR Kit (fluorescent PCR method) produced by Beijing Applied Biological Technologies Co., Ltd. (GXZZ 20203400179) is a 2019-nCoV PCR Kit approved for marketing in China earlier, it is 2019-nCoV antigen test kit just like the Test Kit produced by the Company, both of which are new coronavirus detection products and widely used in clinical practice and generally considered to be of good quality. The purpose and scope of clinical use of this product are the same as the Test Kit. The product is therefore selected as a reference kit for clinical study.

The samples with inconsistent test results in the test group and the control group can be compared and checked by clinical quantitative results and clinical diagnosis results.

3) Names, specifications, sources, lot number, expiry dates and preservation conditions of the products for clinical study

Product name for clinical study is SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), and the specification is 25 tests/kit. The product is provided by the Company. The lot number is 20CG2701X, and its shelf-life is 12 months. The storage condition is 4°C-30°C.

The reference kit is 2019-nCoV PCR Kit (fluorescent PCR method) (GXZZ 20203400179) produced by Beijing Applied Biological Technologies Co., Ltd., the specification is 48 tests/kit, its shelf-life is 6 months and the storage condition is dark place with -20°C±5°C.

4) Quality control method

The execution and completion of clinical trial is inspected on a regular basis. The completeness and precision of clinical sample information is checked and the test results are verified.

5) Clinical trial method

All test samples were simultaneously tested with the control test strip and the Test Kit, and the test results of the two were compared. When all clinical samples were tested, the recorded test results of the Test Kit and the reference kit were statistically analyzed, to calculate the negative coincidence rate, positive coincidence rate and total coincidence rate and then evaluate whether they were equivalent according to these statistical indexes.

6) Statistical analysis methods for clinical study data

Calculate the negative coincidence rate, positive coincidence rate and total coincidence rate of the test results of the Test Kit and the reference kit. Determine whether each index meets the clinical evaluation criteria to validate the accuracy and suitability of the product in clinic. Test the Test Kit with different types of samples and statistically analyze the test results. At the same time, test different types of samples of subjects simultaneously with the Test Kit, and compare the test results. When all clinical samples are tested, the recorded test results are statistically analyzed to calculate the negative coincidence rate, positive coincidence rate and total coincidence rate. And then evaluate whether they are equivalent according to these statistical indexes.

7) Clinical evaluation criteria

Compare the Test Kit with the marketed reference kit to calculate coincidence rate. Product performance shall meet the following requirements.

- 1) Negative coincidence rate: the proportion of samples whose test results obtained with the Test Kit and the reference kit are negative in the samples whose test results obtained with the reference kit are negative. The negative coincidence rate shall be greater than 90%.
- 2) Negative coincidence rate: the proportion of samples whose test results obtained with the Test Kit and the reference kit are positive in the samples whose test results obtained with the reference kit are positive. The positive coincidence rate shall be greater than 90%.
- 3) Total coincidence rate: the proportion of samples whose test results obtained with the Test Kit and the reference kit are the same in the total number of samples. Total coincidence rate shall be larger than 90%.

		Co Positi	ontrol system ve Negative	Total
Test system	Positive Negative	a c	b d	a+b c+d
Total		a+c	b+d	a+b+c+d

Generally, formulas of positive coincidence rate and negative coincidence rate are as follows:

Positive coincidence rate = a/ (a+c) * 100%

Negative coincidence rate = d/ (b+d) * 100%

Total coincidence rate = (a+d)/(a+c+b+d) * 100%

If the positive coincidence rate and negative coincidence rate meet the clinical requirements, the two methods or products are considered to be equivalent; if the difference between the positive coincidence rate and negative coincidence rate is too large, the clinical protocol shall be redesigned.

8) Modification of the protocol during the study

No modification.

V. Results and Analysis of Clinical Trial

A total of 210 samples were selected. All selected samples were tested.

Make consistency statistics on the test results of Test Kit (test product) produced by the Company and the 2019-nCoV PCR Kit, analyze their diagnostic sensitivity and specificity, and list them in the form of four-fold table.

	Test result of	reference kit	Total
Test Kit	Positive	Negative	Total
Positive	True positive (A)	False positive (B)	A+B
Negative	False negative (C)	True negative (D)	C+D
Total	A+ C	B+D	A+B +C+D

Generally, formulas of diagnostic sensitivity and specificity are as follows:

Diagnostic sensitivity = A/ (A+C) × 100%

Diagnostic specificity = D/ (B+D) × 100%

Total coincidence rate= (A+D)/ (A+B+C+D) × 100%

Table 1: Statistics of Test Results of Test Kit and Reference Kit

	Positive result of reference kit	Negative result of reference kit	Total
Positive result of Test Kit	69	1	70
Negative result of Test Kit	6	134	140
Total	75	135	210

Item	Formula	Results	95% CI
Diagnostic sensitivity (%)	A/(A+C)*100%	92.00%	83.63%~96.28%

Diagnostic specificity (%)	D/(B+D)*100%	99.26%	95.92%~99.87%
Total coincidence rate (%)	(a+d)/(a+b+c+d)*100%	96.67%	

It can be seen from Table 1 that among the 75 samples in the positive group tested with the Test Kit, 69 cases are positive and 6 cases are negative. Among the 135 samples in the negative group tested with the Test Kit, 134 cases are negative and 1 cases are positive. The results show that the negative coincidence rate, positive coincidence rate and total coincidence rate all are greater than 90%, indicating that they are in good consistency with those of the reference kit.

VI. Discussion and Conclusion

(I) Discussion

The SARS-CoV-2 antigen rapid test strip produced by the Company contains SARS-CoV-2 N protein monoclonal antibody labeled by colloidal gold that is pre-coated on the colloidal gold labeled pad, SARS-CoV-2 N protein monoclonal antibody fixed in the test area and the corresponding antigen in the quality control area (C). The rapid test of SARS-CoV-2 antibodies in nasal swab samples is used clinically for auxiliary screening of COVID-19 patients. The purpose of the clinical trial is to evaluate the clinical performance of the product. The test conditions are presented as follows:

Comparative analysis results of the Test Kit and 2019-nCoV PCR Kit (fluorescent PCR method) (GXZZ 20203400179) produced by Beijing Applied Biological Technologies Co., Ltd.:

Test results of the Test Kit and the reference kit: The diagnostic sensitivity and specificity are greater than 90%, indicating that they are in good consistency with those of the reference kit.

(II) Test conclusion

After validation, the negative coincidence rate, positive coincidence rate and total colncidence rate between the test results of the Test Kit and 2019-nCoV PCR Kit (fluorescent PCR method) (GXZZ 20203400179) produced by Beijing Applied Biological Technologies Co., Ltd. are relatively high, and the results of the statistical analysis also show that there is no significant difference between the test results of the Test Kit and the reference kit, the two methods have good diagnosis consistency and are equivalent. At the same time, the diagnostic sensitivity and specificity of the Test Kit and the nucleic acid test results are both greater than 90%, indicating that they are in good consistency with those of the reference kit.

VI. Description of Special Circumstances on Clinical Studies

There is no special circumstance to be explained in this clinical study.

Annex I Instruction for Use of All Diagnostic Reagents Used in Clinical Trials

Instruction for Use of the Test Kit



[Product name]

SARS-CoV-2 Antigen Rapid Test Kit Colleidat Gold Immutochranungsphy)

[Model]

restikit; 5 testsikit. 10 testsikit; 25 tesasikit; 50 testsikit.

[Intended Use]

The product is intended for the qualitative detection of antigen against SARS-CoV-2 in clinical samples (masal swab).

Curemeirus, es a large virus family, is sangle positive enundal RNA virus with envelope. The virus kenwent cames and profit interests are to solid, Middle and Respiratory Application (MERS), and Service Actus Respiratory Spatkonic (SARS). The cost precision of SARS-CAV-2 is the N provint and the Respiratory Spatkonic (SARS). The cost precision of SARS-CAV-2 is the N provint anough E-constrained and a spatkonic spatkonic and the spatkonic spatkonic spatkonic and anough E-constrained and a spatkonic spatkon [Summary]

[Principle]

consists of tost cards, Instructions for use, sample treatment solution. And in each test

Model	Tee card	Independents for use	Sample frontment solution
test/kg	1.00		linix.
SINCORES	5 9000	-	IndxI
flassavkk	idustaka idusa	_	Zodvi
Stendarkit	75 tests	-	3m4×?
Branchit	36 12 de		Sentra

The lost eard nomivies of gold standard uses (causted with collicials gold interlied SARS/GAV.2 N SAMS/GAV.2 N mercha monoderal analysis, standard standard restricted to the consider solid an SAMS/GAV.2 N mercha monoderal analogy for quality control area (C) is consider with goat unit monose antitively, absurbing paper, and hydrophashic salfroad.

[Stonage and Stability]

It is would be stored at $4 \leftrightarrow -50^\circ$, be kept day and away from suringfit. The shell life is 12 months, for per rest and, 1 bound be true with within I beaut after unsetting. For per rest and, 1 bound be true within I beaut from the predage label. From the per label and Expurition date are shown in the per label, the II beautiful to the per are shown in the per label, the II beautiful beautiful and the per label.

[Limitation of Procedure]

[Sample Requirements]

 The usal results of this product should be comprehensively judged by the physicite or claim information, and should not be used as the only criterion;
 The product is used to feet the SARS-CoV-2 neighn of the difficial sample, EPrishut Performance Index I Physical Property 1.1 Appearance The product is used to tear the human meal sweb sample.

Sample collection: During the collection procedures for samples, this cent is make proper protection, and avoid further contact into the paragraph of he sample, in same of seculednest contact, its interface insu inextrems thankly the centred out in intent and recessing measures about 60 en texts.

You was the sample, goally and shortly that the each into the arrespharym, through the ment cavity. When vasioner is intermediate the each off more all the prediction counties. A first if we account of classifier, goally in the most found to real this work to which in the color grant of castion, goally procured in the south for that the out the south to which the case of the sample. The sample their establish is though the transfer and temperate before testing in the case while it though the transfer and the case of the case while it though the case of the case of

[Test Method]

The extend through to element imagenf, no berry, no demage, no pollutiver, the medical broad beterrory attenued to the best bound be-terror met not damagen. The sample districts should be their order of the sample districts when the tener without
importance and lines.

The tener furginess report should be no less than 10 marking in 12 Lines for importance speed should be no less than 10 marking in 12 Lines for information should be no less than 10 marking in 12 Lines for the sample of the 12 Lines for the sample of the 12 Lines for the sample of the 13 Lines for the 13 Lines for the 13 Lines of the 13 Lines for the 13 L

Tease read the instruction for use carefully before performing the test. Before testing, resone the

- There is no examinate to reconstruction that the second of the second of the second reconstruction of the second remains the second remains the second remains the second remains a second remains the second remains a second remains a second remains a second remains remains the second remains remains a second remains remai

For the electron of enterprise reference material P2 and P4, the results should be positive and the tendering should be uniform. A Negative reference products uemplicases ratio For the Indicator of ingalive underson, muschil, the augustive deficition ratio should be 100%. For the electrical of ingalive represent compliance can be the electrical of positive reference material, the positive detection rate should be 100%. For the electrical

Cross-tenskripy. This test device has no erost reactivity with concausity human corearvints OCTs, influence a vive, influence B virus, respiratory sprayidal virus, additionins, Ed vivus, meakes virus, cyturolegiolovintus, tutarkins, Norresions, mumps virus, varicella zenter virus, mycophacna pmeunomiae, illuman modunpetamovinus.

[Processions]

- 1. The next entry stands be precisional to use in vito auxiliare distances. Do not use capitot products.
 2. Does freeze et ous alter the experience des (estit posibigain for the expension edse).
 3. Avoid coxestive temporatue and brainfarth in the opportunent environment. The servicion temporature attention of the bestoo with.
 3. Avoid coxestive temporatue and brainfarth in the opportunent environment. The expension is important attention of the bestoo with.
 3. Avoid coxestive temporature distributed and is about a total to altitude environment. The expension of the comparation of the contraction of the contraction

ofter 15 min.

Remove the protective cover of the fixing glue. Stick the left and eight adea together,

[Explanation of Symbols]

(2)	DO SOFTURE IF PARICAGE IN DAMAGED	8	CONSELT INSTRUCTIONS FOR USP
8			USB-BY DATE
***************************************	-	FV)	DATE OF SONN PACTORS.
I	MANETACTINEE	Lou	RATEITCODE
*	SZEFAWAS PROM SUBLIGHT	*	KRETORN
(9/8)	IN VOTRO DENZABELE METRICAL DE VICE	CE	CT MARK
(A)	AUTHOUZED REPRESENTATIVE IN		

 Negative (-). There is only one pumple stripe in the quality control area (C), and without pumple stripe in either test area (T). C Coested Line
T Pest Line

I The Explanation of the Testing Results 1

C CONTROL LINE
T CONTROL LINE
Positive

Invalid: There is no pumple stripe in the quality control areas (C), or there is blue stripe in the quality
of not one of the control and control and control and control and areas of the control as better discontrol.
Unless his contribute, it went much the memoritum for use again amendal, such has med her mere last earlier than the control and the products with stane lost number and control food supplies medial-lastists, soop using the products with stane lost number and control food supplies immediately.

Petjing Leye Medical Technology Co., Ltd. Address: Building 7-1 No.37 Chooqsan Nead. Chengping District. Beijing, 102236, P.R. Clains Tel: +86-19-80123964

Emait: lepusztwiee@lepunso Web: en.lepunedlesLeom

test time

LECHEE Leyn Medical (Europe) Corporatel U.A.
Abe Lewin Boalevard 36, 8448 JB, Hoemaven, The Netherlands
Tel: 131-515-873399 Fax: 131-515-760020

I Approval Date and Revision Dare of the Instruction I

Approved on Ind., Sept., 2020. Version number, CL-InCO27 REV.01

Annex II Clinical Trial Data

Sample number	Test result of Product tested	Test result of reference product
1	positive	positive
2	negative	negative
3	positive	positive
4	negative	
5	negative	negative
6		negative
7	negative	negative
8	positive	positive
	positive	positive
9	positive	positive
10	negative	negative
11	negative	negative
12	negative	negative
13	positive	positive
14	positive	positive
15	positive	positive
16	negative	negative
17	negative	negative
18	positive	negative
19	positive	positive
20	negative	negative
21	negative	negative
22	negative	negative
23	negative	negative
24	negative	negative
25	positive	positive
26	negative	negative
27	negative	negative
28	positive	positive
29	negative	negative
30	negative	negative
31	negative	negative
32	negative	negative
33	negative	negative
34	negative	negative
35	positive	positive
36	negative	negative
37	positive	positive
38	negative	negative
39	negative	negative
40	negative	negative
41	positive	positive
42	negative	negative
43	negative	negative
44	negative	negative
45		
+3	negative negative	negative negative

47	positive	positive
48	negative	positive
49	negative	negative
50	positive	positive
51	negative	negative
52	negative	negative
53	positive	positive
54	positive	positive
55	negative	positive
56	positive	positive
57	negative	negative
58	negative	negative
59	negative	negative
60	negative	negative
61	negative	negative
62	positive	positive
63	negative	negative
64	positive	positive
65	negative	negative
66	negative	negative
67	positive	positive
68	negative	negative
69	negative	negative
70	negative	negative
71	negative	negative
72	positive	positive
73	negative	negative
74	negative	negative
75	positive	positive
76	negative	negative
77	positive	positive
78	positive	positive
79	negative	negative
80	positive	positive
81	negative	negative
82	negative	negative
83	positive	positive
84	negative	negative
85	negative	negative
86	negative	negative
87	negative	positive
88	positive	positive
89	negative	negative
90	negative	negative
91	positive	positive
92	negative	positive
93	negative	negative
94	positive	positive
95	positive	positive
96	negative	negative

97	positive	positive
98	negative	negative
99	negative	negative
100	negative	negative
101	negative	negative
102	negative	negative
103	positive	positive
104	negative	negative
105	negative	negative
106	negative	negative
107	positive	positive
108	negative	positive
109	positive	positive
110	positive	positive
111	negative	negative
112	negative	negative
113	negative	negative
114	negative	negative
115	positive	positive
116	negative	negative
117	positive	positive
118	negative	negative
119	negative	negative
120	negative	negative
121	positive	positive
122	positive	positive
123	positive	positive
124	negative	positive
125	negative	negative
126	negative	negative
127	negative	negative
128	positive	positive
129	negative	negative
130	negative	negative
131	positive	positive
132	negative	negative
133	positive	positive
134	negative	negative
135	negative	negative
136	negative	negative
137	negative	negative
138	positive	positive
139	positive	positive
140	negative	negative
141	positive	positive
. 142	negative	negative
143	negative	negative
144	negative	negative
145	negative	negative
146	positive	positive
UTU	positive	positive

147	negative	negative
148	positive	positive
149	negative	negative
150	negative	negative
151	negative	negative
152	negative	negative
153	negative	negative
154	negative	negative
155	negative	negative
156	negative	negative
157	negative	negative
158	negative	negative
159	positive	positive
160	negative	negative
161	negative	negative
162	negative	negative
163	negative	negative
164	positive	positive
165	positive	positive
166	positive	positive
167	negative	negative
168	positive	positive
169	positive	positive
170	negative	negative
171	positive	positive
172	negative	negative
173	negative	negative
174	negative	negative
175	negative	negative
176	negative	negative
177	negative	negative
178	positive	positive
179	negative	negative
180	positive	positive
181	positive	positive
182	positive	positive
183	positive	positive
184	negative	negative
185	negative	negative
186	negative	negative
187	negative	negative
188	negative	negative
189	negative	negative
190	negative	negative
191	negative	negative
192	positive	positive
193	negative	
194	negative	negative
195	positive	negative
196		positive
190	negative	negative

197	positive	positive
198	negative	negative
199	positive	positive
200	negative	negative
201	negative	negative
202	negative	negative
203	negative	negative
204	positive	positive
205	positive	positive
206	negative	negative
207	negative	negative
208	negative	negative
209	positive	positive
210	negative	negative